July 25, 2001

By Bob Kuska

Posted in: leukemia

Tags: antibody, BL23, chemotherapy, immunotoxin, leukemia, recombinant, remission, toxin, trial

Objectives

I. Assess the therapeutic efficacy and toxicity of the recombinant immunotoxin LMB-2, an anti-Tac murine monoclonal antibody fragment conjugated to a truncated portion of Pseudomonas exotoxin, in patients with Tac-expressing leukemias and lymphomas.

II. Define the pharmacokinetics of LMB-2, including the terminal elimination serum half-life, area under the curve, and volume of distribution.

III. Evaluate, in a preliminary manner, the immunogenicity of LMB-2 in these patients.

IV. Determine the effect of LMB-2 on various components of the circulating cellular immune system.